Search

Displaying results 3171 - 3180 of 10000 in total
  1. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

  2. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    [A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.

  3. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  4. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]

  5. Drug

    Ethionamide

    go.drugbank.com/drugs/DB00609
    ApprovedInvestigationalWithdrawn

    A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)

  6. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    ) to sinus rhythm in adults. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  7. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.

  8. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888] … Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase.

  9. Drug

    Quinidine barbiturate

    go.drugbank.com/drugs/DB01346
    Approved

    A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909) … The administration of quinidine derivatives helps to observe various skin and mucosal reactions.

  10. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the prevention of angina.